{"organizations": [], "uuid": "f99192d7333e63e5894bc1f5e16195b09a0e81cc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s2.reutersmedia.net/resources/r/?m=02&d=20180103&t=2&i=1219094744&w=1200&r=LYNXMPEE020YC", "site_section": "https://www.reuters.com/", "section_title": "Business &amp; Financial News, U.S &amp; International Breaking News | Reuters", "url": "https://www.reuters.com/article/us-allergan-layoffs/allergan-to-cut-over-1000-jobs-as-it-works-to-return-to-growth-idUSKBN1ES1HN", "country": "US", "domain_rank": 408, "title": "Allergan to cut over 1,000 jobs as it works to return to growth", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.056, "site_type": "news", "published": "2018-01-04T00:59:00.000+02:00", "replies_count": 0, "uuid": "f99192d7333e63e5894bc1f5e16195b09a0e81cc"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/us-allergan-layoffs/allergan-to-cut-over-1000-jobs-as-it-works-to-return-to-growth-idUSKBN1ES1HN", "ord_in_thread": 0, "title": "Allergan to cut over 1,000 jobs as it works to return to growth", "locations": [], "entities": {"persons": [{"name": "chizu nomiyama", "sentiment": "none"}, {"name": "michael ermanediting", "sentiment": "none"}], "locations": [{"name": "new york", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "allergan", "sentiment": "negative"}, {"name": "allergan plc", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEW YORK (Reuters) - Allergan Plc ( AGN.N ) on Wednesday said it plans to cut over 1,000 jobs and eliminate an additional 400 currently open positions, as it works to cut costs in the face of new competition for its second most important drug, dry-eye treatment Restasis.\nThe company said the jobs and positions it plans to eliminate mostly focus on products and categories where the company has or expects to soon lose exclusivity.\nThe drugmaker said it expects to take a $125 million charge from the job cuts, primarily due to severance, most of which will be recorded in the fourth quarter of 2017.\nAllergan said cost savings from this restructuring program\nshould be around $300 million to $400 million per year.\nReporting by Michael ErmanEditing by Chizu Nomiyama\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-04T00:59:00.000+02:00", "crawled": "2018-01-03T19:26:10.002+02:00", "highlightTitle": ""}